-
AI, Machine Learning & Computational Biology2 days agoFlagship joins three biotechs together to form Etcelera
Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.
-
Capital, M&A & Industry Strategy2 days agoDren Bio pockets $350m for rare blood cancer programme
Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.
-
Capital, M&A & Industry Strategy2 days agoUS gives $99m for Ebola jab project, as cases spread in Africa
As Africa's CDC chief warns "unprecedented" Ebola outbreak could spread to other parts of the world, the US awards R&D funding to an IAVI vaccine.
-
Global Biotechnology & Pharmaceutical Markets2 days agoLilly’s tirzepatide juggernaut is still gathering momentum
Lilly shrugs off concerns about the effect of US drug pricing policies on its diabetes and weight loss drugs as revenues leap 39% to $24.4bn.
-
Global Biotechnology & Pharmaceutical Markets3 days agoGSK shares come under pressure from weaker vaccine sales
Shares in GSK fell on a decline in vaccine sales in Q3, although demand for other drugs was strong with signs that its revamp is starting...
-
Regulatory Intelligence & Drug Approvals3 days agoAbbVie bids to join the BCMA crowd with etentamig
AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
-
Capital, M&A & Industry Strategy4 days agoNovartis takes $1.9bn hit from Avidity takeover in Q3
Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.
-
Capital, M&A & Industry Strategy4 days agoAnthropic sets out its biopharma ambitions in IPO doc
Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."
-
Clinical Trials & Development7 days agoESMO26: Lily’s sofe-m ADC stakes a claim in ovarian cancer
Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
-
Clinical Trials & Development7 days agoESMO26: Lilly’s sofe-m ADC stakes a claim in ovarian cancer
Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
